Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris
Launched by LEO PHARMA · Sep 15, 2005
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
A phase IV study of different treatment regimens of calcipotriol 50 mcg/g cream and combination (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) ointment following treatment with combination ointment in psoriasis vulgaris
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with psoriasis vulgaris of trunk and/or limbs
- Exclusion Criteria:
- • -
About Leo Pharma
LEO Pharma is a global pharmaceutical company dedicated to developing innovative therapies for dermatological and critical care conditions. With a strong focus on research and development, LEO Pharma aims to improve the lives of patients through advanced treatments and a commitment to high-quality standards. The company collaborates with healthcare professionals and stakeholders to address unmet medical needs and drive scientific progress in the field. Through its clinical trials, LEO Pharma seeks to enhance therapeutic options and provide effective solutions for patients suffering from skin diseases and other related health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gent, , Belgium
Hamilton, Ontario, Canada
Saint Etienne, , France
Frankfurt, , Germany
Nijmegen, , Netherlands
Terrassa, , Spain
Merseyside, , United Kingdom
Patients applied
Trial Officials
S White, MD
Principal Investigator
Clatterbridge Hospital, Department of Dermatology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials